← Retour à la une
Asie · Marchés régionaux · Pulse (Maeil Business)

Celltrion’s Remsima, Herzuma lead market share in major Asian countries

Publié par Pulse (Maeil Business) · Corée du Sud il y a 17 h
(Celltrion)
(Celltrion) · Pulse (Maeil Business)

Résumé détaillé

Truxima (rituximab), a treatment for blood cancer, recorded market shares of 92 percent in Singapore, 78 percent in Thailand, and 41 percent in Hong Kong. Celltrion attributed the…

South Korean biopharmaceutical company Celltrion Inc. said Thursday that its treatments for autoimmune diseases and cancer are strengthening their market positions in major Asian countries.

Celltrion said its Remsima (infliximab) portfolio for autoimmune diseases ranked No. 1 by prescription share in the second quarter, with market shares of 95 percent in Singapore, 83 percent in Hong Kong, and 75 percent in Malaysia.

Herzuma (trastuzumab), a treatment for breast and gastric cancers, also maintained its leading position, with market shares of 67 percent in Hong Kong, 59 percent in Thailand, and 52 percent in Malaysia.

Truxima (rituximab), a treatment for blood cancer, recorded market shares of 92 percent in Singapore, 78 percent in Thailand, and 41 percent in Hong Kong.

Celltrion attributed the results to its direct-sales strategy tailored to the characteristics of each market.

The company has pursued sales strategies customized to local demand, primarily through its subsidiaries in Malaysia, Singapore, and Thailand.

Celltrion plans to accelerate its revenue growth through a series of new product launches.

The company plans to launch Vegzelma (bevacizumab), a biosimilar to Roche’s Avastin for cancer treatment, in Hong Kong this month, and Stoboclo (denosumab), a treatment for bone loss, in Thailand in December.

In February next year, it plans to launch Eydenzelt (aflibercept), a treatment for eye diseases, in Singapore and Omlyclo (omalizumab), a treatment for allergic and inflammatory conditions, in Thailand.

Début de l'article, extrait de Pulse (Maeil Business). Pour lire la suite, ouvrez l'article chez le média.

Lire l'article complet sur Pulse (Maeil Business) Connectez-vous pour sauvegarder

MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (pulse.mk.co.kr)

À lire aussi